Description
There is great interest in stem cells because they have potential to replace defective or damaged cells resulting from a variety of disorders and injuries, leading to a range of new regenerative therapies. Stem cells also have value as a research tool, as their in vitro study would allow scientists to learn more about the function of various organs and the development of particular diseases; stem cells may also eventually permit drug developers to test emerging therapies on diseased cells.
For market-watchers in the pharmaceutical industry, the question is what potential they have and where they could take the pharmaceutical market. New scientific developments and recent changes in the U.S. Federal government’s policy towards stem cells have made this potential more relevant. Kalorama Information has tackled the question in Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development. Kalorama analyst Alison Sahoo has built models to determine the best, moderate and worst case scenarios for the three key markets for stem cells:
- Stem Cells in Drug Development
- Stem Cells in Cord Blood Banking
- Stem Cell Therapeutics
The potential of stem cell therapeutics is provided, broken down by disease:
- Cardiovascular disease
- Lung disease
- Tooth disease
- Arthritis
- Wrinkles/aging skin
- Incontinence
- Osteoporosis
- Diabetes
- Cancer
- Bladder disease
- Infertility
- Orthopedics
- Alzheimer’s disease
- Burns (severe)
- Lupus
- Parkinson’s disease
- Liver failure
- Multiple sclerosis
- Critical limb ischemia
- Intestinal disease
- Sickle cell disease
- Multiple myeloma
- NH Lymphoma
- Leukemia
The following trends are discussed in this report:
- Ethical Questions
- U.S. – State and Federal Initiatives
- Research Funding
- Cord Blood Initiatives
- International Initiatives
- Stem Cell Patents
- Other Healthcare Regulations
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at
http://kaloramakeypoint.blogspot.com/
Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodolgy
- Introduction
- Current Stem Cell Therapies
- Developmental Stem Cell Therapies
- Issues In Stem Cell Research
- Stem Cell Forecasts
CHAPTER TWO: INTRODUCTION
- The Promise of Stem Cells In Medical Treatment
- Types of Stem Cells
- Embryonic Stem Cells
- Adult Stem Cells
- Cord Blood Stem Cells
- Stem Cell Harvesting
- Embryonic Stem Cells
- Therapeutic Cloning
- Unfertilized Eggs
- Adult Stem Cells
- Leukapheresis
- Peripheral Blood
- Cord Blood Stem Cells
- Transplantation Approaches
- Autologous Transplantation
- Allogenic Transplantation
- Transplantation Procedures
- Cancerous Stem Cells
- Other Harmful Stem Cells
- Stem Cells in Drug Development
- Stem Cell Therapeutics
- Stem Cells Targeting Drugs
- Stem Cell Generated Organs
CHAPTER THREE: CURRENT STEM CELL THERAPIES
- Cancer
- Leukemia
- Gene Therapy
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Non Cancerous Diseases
- Aplastic anemia
- Immunodeficiency
- Lupus
- Sickle Cell Disease
- Other Conditions
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
- Alzheimer’s Disease
- Arthritis
- Bladder Disease
- Burns
- Cancer
- Cardiovascular Conditions
- Critical Limb Ischemia
- Diabestes
- Esophagal Disease
- Incontinence
- Infertility
- Intestinal Disease
- Liver Failure
- Lung Disease
- Multiple Sclerosis
- Orthopedics
- Osteoporosis
- Parkinson’s Disease
- Sickle Cell Disease
- Tooth Disease
- Wrinkles/Aging Skin
CHAPTER FIVE: STEM CELL FORECASTS
- Best Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
- Most Likely Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
- Worst Case
- Stem Cell Therapeutics
- Umbilical Cord Blood Banking
- Fees Related to Drug Development
CHAPTER SIX: ISSUES IN STEM CELL RESEARCH
- Ethical Questions
- U.S. – State and Federal Initiatives
- Research Funding
- Federal Funding
- State Funding
- Cord Blood Initiatives
- International Initiatives
- Stem Cell Patents
- Other Healthcare Regulations
LIST OF EXHIBITS CHAPTER ONE: EXECUTIVE SUMMARY
- Table 1-1 Total Market for Stem Cell Technologies in $ Millions, 2010 – 2020
- Table 1-2 Stem Cell Therapeutics Market in $ Millions, 2010 – 2020
- Table 1-3 Total Market for Cord Blood Banking Fees in $ Millions, 2010 – 2020
- Table 1-4 Total Market for Stem Cell Drug Development Technologies in $ Millions, 2010 – 2020
- Figure 1-1 Total Market for Stem Cells – Most Likely Case in $ Millions, 2010 – 2020
CHAPTER TWO: INTRODUCTION
- Table 2-1 Established and Emerging Artificial Organ Products by Market Segment, 2010
CHAPTER THREE: CURRENT STEM CELL THERAPIES
- Table 3-1 Types of Leukemia, 2011
CHAPTER FOUR: DEVELOPMENTAL STEM CELL THERAPIES
- Table 4-1 Global Disease Populations Addressed by Potential Stem Cell Therapies, 2011
- Table 4-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2010 and 2020
- Table 4-3 Estimated and Projected World Cancer Mortality by Selected Types of Cancer, 2010 and 2020
- Table 4-4 Features and Types of Urinary Incontinence, 2011
- Table 4-5 Types and Causes of Male Infertility, 2011
- Table 4-6 Common Diseases of the Lungs, 2011
CHAPTER FIVE: STEM CELL FORECASTS
- Table 5-1 Persons Affected by Key Stem Cell Therapeutic Targets in Millions, 2011
- Table 5-2 Best Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
- Table 5-3 Best Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
- Table 5-4 131 Best Case: Cord Blood Banking Revenues in $ Millions, 2007 – 2020
- Table 5-5 Best Case: Stem Cell-Based Drug Development Technology Fees, 2010 – 2020
- Table 5-6 Best Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 – 2020
- Table 5-7 Most Likely Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
- Table 5-8 Most Likely Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
- Table 5-9 Most Likely Case: Cord Blood Banking Revenues in $ Millions, 2010 – 2020
- Table 5-10 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010 – 2020
- Table 5-11 Most Likely Case: Stem Cell-Based Drug Development Technology Fees in $ Millions, 2010 – 2020
- Table 5-12 Worst Case: Procedure Volume for Proprietary Stem Cell Therapies by Disease in Millions, 2010 – 2020
- Table 5-13 Worst Case: Revenues for Proprietary Stem Cell Therapies by Disease in $ Millions, 2010 – 2020
- Table 5-14 Worst Case: Cord Blood Banking Revenues in $ Millions, 2010-2020
- Table 5-15 Worst Case: Stem Cell-Based Drug Development Technology Fees in Millions, 2010-2020
- Table 5-16 Worst Case: Stem Cell-Based Drug Development Technology Fees in $ Millions 2010-2020
CHAPTER SIX: ISSUES IN STEM CELL RESEARCH
- Table 6-1 NIH Funding for Stem Cell Research, 2002 – 2010 in $ Million
- Table 6-2 U.S. State Embryonic & Fetal Research Laws
- Table 6-3 Positions on Human ES Cell Research by Country, 2011
- Table 6-4 EU Laws on hESC Research by Country
